Trans-oral incisionless fundoplication vs stretta, two recognized endoluminal anti-reflux therapies; a systematic review and meta-analysis

Authors

  • Reece-Bolton Obuobi Department of GI and Laparoscopic, James Cook University Hospital, Middlesbrough, Cleveland, UK http://orcid.org/0000-0003-3880-1172
  • Yirupaiahgari Viswanath Department of GI and Laparoscopic, James Cook University Hospital, Middlesbrough, Cleveland, UK
  • Rajeev Sathasivam Department of GI and Laparoscopic, North Tees University Hospital, Stockton on Tees, Cleveland, UK
  • Gopinath Bussa Department of GI and Laparoscopic, North Tees University Hospital, Stockton on Tees, Cleveland, UK
  • Talvinder Gill Department of GI and Laparoscopic, North Tees University Hospital, Stockton on Tees, Cleveland, UK
  • Anil Reddy Department of GI and Laparoscopic, James Cook University Hospital, Middlesbrough, Cleveland, UK
  • Venkat Shanmugam Department of GI and Laparoscopic, North Tees University Hospital, Stockton on Tees, Cleveland, UK
  • Andy Gilliam Department of GI and Laparoscopic, Darlington memorial Hospital, Darlington, UK
  • Prem Thambi Department of GI and Laparoscopic, North Tees University Hospital, Stockton on Tees, Cleveland, UK

DOI:

https://doi.org/10.18203/2349-2902.isj20180795

Keywords:

EsophyX, Endoluminal, Gastroesophageal reflux disease, Stretta, Trans-oral incisionless fundoplication

Abstract

Gastro-oesophageal reflux disease (GORD) is common with a prevalence of 10-20% in the Western World. During the last two decades, amongst introduced several endo-luminal techniques, evidence has emerged about the efficacy and safety of two treatment modalities for GORD; 'Stretta' procedure and trans-oral incisionless fundoplication (TIF)' or EsophyX. Author in this study aim to conduct a systematic review of published 'level 1' evidence, to evaluate all evidence on the efficacy of Stretta procedure and TIF (EsophyX) for the management of GORD. A robust literature that included RCT trials only, searched on MEDLINE, EMBASE, and Cochrane library was undertaken from January 2007 until January 2017. The outcomes were normalisation of oesophageal pH values, augmentation of lower oesophageal sphincter pressure (LESP), health-related quality of life (HRQOL) score, and ability to stop or reduce PPI after procedure. For quality assurance purposes, two researchers were involved in the data collection process and its analysis. Author collected data from 9 RCT trials, 3 for Stretta and 6 for EsophyX. From the Stretta trials 101 patients were recruited, 92 patients were analyzed.  Of the EsophyX trials, 3 of six papers were from single trial. A total of 296 patients were included and 203 were analysed. The pooled results show both stretta and esophyX significantly improved GORD symptoms. In a meta-analysis of trials, author found that both Stretta and EsophyX significantly improves GERD-HRQL score and enables patients to reduce or stop PPI intake compared with sham/PPI therapy alone. The overall quality of evidence is superior for EsophyX than it is for Stretta.

References

Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet. 1990;335(8683):205-8.

Mattar SG, Qureshi F, Taylor D, Schauer PR. Treatment of refractory gastroesophageal reflux disease with radiofrequency energy (Stretta) in patients after Roux-en-Y gastric bypass. Surgical Endoscopy and Other Interventional Techniques. 2006 Jun 1;20(6):850-4.

He J, Ma X, Zhao Y, Wang R, Yan X, Yan H, et al. A population-based survey of the epidemiology of symptom-defined gastroesophageal reflux disease: The Systematic Investigation of Gastrointestinal Diseases in China. BMC Gastroenterol. 2010;10(1):94.

Nocon M, Labenz J, Jaspersen D, Meyer‐Sabellek W, Stolte M, Lind T, et al. Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study. J Gastroenterol Hepatol. 2007 Nov 1;22(11):1728-31.

Galmiche JP. Non-erosive reflux disease and atypical gastro-oesophageal reflux disease manifestations: treatment results. Drugs. 2006;66(1):7-13.

Locke G, Talley NJ, Fett SL, Zinsmeister AR, Melton LR. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterol. 1997;112(5):1448-56.

Anderson WD, Strayer SM, Mull SR. Common questions about the management of gastroesophageal reflux disease. Am Family Phys. 2015;91(10):692-7.

Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PloS one. 2015;10(6):e0124653.

Perry KA, Banerjee A, Melvin WS. Radiofrequency energy delivery to the lower esophageal sphincter reduces esophageal acid exposure and improves GERD symptoms: a systematic review and meta-analysis. Surg Laparosc Endosc Percut Tech. 2012;22(4):283-8.

Aziz AM, El-Khayat HR, Sadek A, Mattar SG, McNulty G, Kongkam P, et al. A prospective randomized trial of sham, single-dose Stretta, and double-dose Stretta for the treatment of gastroesophageal reflux disease. Surg Endosc. 2010;24(4):818-25.

Arts J, Bisschops R, Blondeau K, Farre R, Vos R, Holvoet L, et al. A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastro-esophageal junction in GERD. Am J Gastroenterol. 2012 Feb;107(2):222.

Coron E, Sebille V, Cadiot G, Zerbib F, Ducrotte P, Ducrot F, et al. Clinical trial: radiofrequency energy delivery in proton pump inhibitor‐dependent gastro‐oesophageal reflux disease patients. Aliment Pharmacol Therapeut. 2008 Nov 1;28(9):1147-58.

Trad KS, Barnes WE, Simoni G, Shughoury AB, Mavrelis PG, Raza M, et al. Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO randomized clinical trial. Surg Inn. 2015;22(1):26-40.

Trad KS, Fox MA, Simoni G, Shughoury AB, Mavrelis PG, Raza M, et al. Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm. Surg Endosc Intervent Tech. 2016;1-11.

Trad KS, Fox MA, Simoni G, Shughoury AB, Mavrelis PG, Raza M, et al. 724 Efficacy of Transoral Fundoplication for Treatment of Chronic Gastroesophageal Reflux Disease Incompletely Controlled With High-Dose PPI Therapy: A Randomized, Multicenter, Open Label, Crossover Study. Gastroenterol. 2014 May 1;146(5):S-127.

Hunter JG, Kahrilas PJ, Bell RC, Wilson EB, Trad KS, Dolan JP, et al. Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial. Gastroenterol. 2015 Feb 1;148(2):324-33.

Witteman BP, Conchillo JM, Rinsma NF, Betzel B, Peeters A, Koek GH, et al. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2015;110(4):531-42.

Håkansson B, Montgomery M, Cadiere GB, Rajan A, Varannes BS, et al. Randomised clinical trial: transoral incisionless fundoplication vs. sham intervention to control chronic GERD. Aliment Pharmacol Therapeut. 2015;42(11-12):1261-70.

Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clini Gastroenterol Hepatol. 2015;13(6):1058-67.

Punnoose S, Sathasivam R, Reece-Bolton O, Thambi P, Dhar A, Viswanath Y. PWE-087 Endoscopic Non-Ablative Radio Frequency Energy Treatment (Stretta®) for Gastro-Oesophageal Reflux Disease–The First UK Single Centre Experience. Gut. 2016;65:A181.

Perry KA, Banerjee A, Melvin WS. Radiofrequency energy delivery to the lower esophageal sphincter reduces esophageal acid exposure and improves GERD symptoms: A systematic review and meta-analysis. Surg Laparosc Endosc Percut Tech. 2012;22(4):283-8.

Dughera L, Catalano G, Cisarò F, Cassolino P. P. 08.7 The use of non-ablative Rf energy (stretta) for the treatment of gerd, what happens a decade later. Digest Liver Dis. 2016 Feb 24;48:e167.

Wendling MR, Melvin WS, Perry KA. Impact of transoral incisionless fundoplication (TIF) on subjective and objective GERD indices: a systematic review of the published literature. Surg Endosc. 2013;27(10):3754-61.

Downloads

Published

2018-02-26

Issue

Section

Review Articles